|
May 23
|
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
|
|
May 23
|
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
|
|
May 22
|
Bitcoin soars, Fannie Mae & Freddie Mac, Novo's GLP-1 discount
|
|
May 22
|
Novo Nordisk battles Wegovy copycats through discounted prices, legal threats
|
|
May 22
|
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
|
|
May 22
|
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
|
|
May 22
|
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
|
|
May 22
|
Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays
|
|
May 22
|
Novo Nordisk's former chief makes comeback to steer choice of new CEO
|
|
May 22
|
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change
|
|
May 21
|
BMO Capital Maintains Cautious Outlook on Novo Nordisk Amid CEO Transition
|
|
May 20
|
Novo Nordisk Places Bet on CEO Shake-Up to Reclaim Edge in Weight Loss Drug Race
|
|
May 20
|
Why Novo Nordisk Stock Popped on Tuesday
|
|
May 20
|
Novo Nordisk Woes Just Hit Denmark’s Economy. The Stock Is Rising.
|
|
May 20
|
What Makes Novo Nordisk (NVO) a Lucrative Investment?
|
|
May 20
|
Weight-loss company Noom pivots to smaller doses of compounded Wegovy
|
|
May 19
|
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
|
|
May 19
|
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie
|
|
May 19
|
Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns
|
|
May 19
|
Novo Nordisk’s CEO to step down as weight loss market share plummets
|